share_log

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

Benzinga ·  Aug 5 15:42  · Ratings

HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19 from $2 (1-10 Reverse Stock Split).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment